Galderma Group AG (XSWX:GALD) Other Stockholders Equity: CHF71 Mil (As of Dec. 2025)


XSWX:GALD Galderma Group AG XSWX:GALD
15 GF Score
Price CHF178.85
! 4 Warning Signs
View Full Analysis

What is Galderma Group AG Other Stockholders Equity?

Galderma Group AG XSWX:GALD -2.75% 15 Other Stockholders Equity is CHF71 Mil as of Dec. 2025. GuruFocus rates XSWX:GALD with a GF Score™ of 15/100. The stock has 4 warning signs investors should review.

Galderma Group AG's Other Stockholders Equity for the quarter that ended in Dec. 2025 was CHF71 Mil.

Galderma Group AG's quarterly Other Stockholders Equity increased from Dec. 2024 (CHF-6 Mil) to Jun. 2025 (CHF60 Mil) and increased from Jun. 2025 (CHF60 Mil) to Dec. 2025 (CHF71 Mil).

Galderma Group AG's annual Other Stockholders Equity declined from Dec. 2023 (CHF10 Mil) to Dec. 2024 (CHF-6 Mil) but then increased from Dec. 2024 (CHF-6 Mil) to Dec. 2025 (CHF71 Mil).

Galderma Group AG Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Galderma Group AG's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG Other Stockholders Equity Chart

Galderma Group AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
0.00 0.00 9.51 -6.24 70.92

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial 9.51 26.81 -6.24 60.18 70.92
XSWX:GALD
15GF Score
Galderma Group AG XSWX:GALD
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galderma Group AG Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of CHF71 Mil mean?
Galderma Group AG (XSWX:GALD) has a Other Stockholders Equity of CHF71 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Galderma Group AG and its competitors.
Is Galderma Group AG's Other Stockholders Equity too high?
Galderma Group AG's current Other Stockholders Equity is CHF71 Mil. Overall, Galderma Group AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Other Stockholders Equity compare to ZTS and UTHR?
Galderma Group AG's Other Stockholders Equity of CHF71 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Galderma Group AG and its competitors. Galderma Group AG's current Other Stockholders Equity is CHF71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current Other Stockholders Equity of CHF71 Mil. The current Other Stockholders Equity is CHF71 Mil. Galderma Group AG's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current Other Stockholders Equity is CHF71 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galderma Group AG Business Description

Address Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
15GF Score

Get the complete analysis for XSWX:GALD

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF178.85
Price